|
 |
Hematological malignanciesThis page contains recent news articles, when available, and an overview of Hematological malignancies but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Background information on Hematological malignancies
FOXBusiness...rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that it will release its 2007 Pfizer to acquire privately-held Serenex - Mar 3, 2008 CNNMoney.com...the rights to SNX-5422, an oral Hsp90 inhibitor currently in Phase I trials for the potential treatment of solid tumors and hematological malignancies. SuperGen to Present at Susquehanna SIGnificant Options in ... - Feb 26, 2008 PR Newswire (press release),...rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that James S. Manuso, Ph.D., Pfizer Acquires Serenex for Undisclosed Amount - Mar 3, 2008 Therapeutics Daily (subscription) (press release),...to an oral Hsp90 inhibitor, SNX-5422, currently in Phase I trials for the potential treatment of solid tumors and hematological malignancies, Pfizer Synta Pharmaceuticals Corp. Q4 2007 Earnings Call Transcript - Mar 20, 2008 Seeking Alpha,These cancers include, in addition to melanoma, breast, prostrate, ovarian, pancreatic, and hematological malignancies. We believe the favorable safety Celgene Completes $2.9 Bln Acquisition Of Pharmion - Update - Mar 7, 2008 Trading Markets (press release),In addition, we have a number of innovative programs encompassing therapies for immune/inflammatory disorders, hematological malignancies and other cancers MethylGene Reports Fourth Quarter and Full Year 2007 Financial Results - Mar 7, 2008 FOXBusinessMGCD0103, is an oral isotype-selective HDAC inhibitor presently in multiple clinical trials for solid tumors and hematological malignancies, SuperGen Reports 2007 Fourth Quarter and Annual Financial Results - Mar 3, 2008 Earthtimes,...of therapies for solid tumors and hematological malignancies, today reported financial results for the fourth quarter and year ended December 31, 2007. VioQuest Pharmaceuticals Enters Into Clinical Trial Agreement for ... - Feb 26, 2008 Business Wire (press release),...a targeted inhibitor of Akt phosphorylation, which is currently being tested in Phase I clinical trials in both solid and hematological malignancies; Pfizer plans to acquire NC-based biotech - Mar 3, 2008 The Bay City Times - MLive.com,Serenex has a drug candidate, SNX-5422, in Phase I trials for the potential treatment of solid tumors and hematological malignancies (the types of cancer International Journal Of Hematology To Be Published By Springer - Mar 3, 2008 Medical News Today (press release),...leukocytes and hematopoiesis, hemostasis, thrombosis and vascular biology, hematological malignancies, transplantation and cell therapy. Transplant offers hope for Early - Feb 27, 2008 Rockmart Journal,...formerly known as “preleukemia� and is classified as one of a diverse collection of hematological malignancies united by ineffective production of blood SuperGen to Highlight Oncology Pipeline Data in Multiple ... - Dec 3, 2007 CNNMoney.com...rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that multiple abstracts have been Data Indicate That SuperGen's Lead JAK2 Kinase Inhibitors Prevent ... - Dec 10, 2007 CNNMoney.comEntitled "Targeting the JAK2 in Hematological Malignancies," the poster described how SuperGen used its CLIMB(TM) technology to build several models that SuperGen to Present at BMO Capital Markets Focus on Healthcare ... - Nov 27, 2007 CNNMoney.com...rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that Gregory Berk, MD, Serenex Announces Initiation of Second Phase 1 Trial for Oral ... - Dec 4, 2007 Market Wire (press release)The phase 1 study will be a dose escalation trial involving up to 50 patients with hematological malignancies. The trial will evaluate safety, Serenex Launches Second Clinical Trial of Potential Cancer Drug - Dec 4, 2007 WRAL.com,Sernex has launched a second Phase I clinical trial of a potential cancer drug, this time targeting hematological malignancies. Hematological malignancies S*BIO's Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic ... - Dec 10, 2007 Earthtimes,SB1317, a novel potent inhibitor of FLT3 kinase and CDKs 1, 2 and 9, demonstrated therapeutic potential for the treatment of hematological malignancies. Pharmion and MethylGene Present Favorable Clinical Data From ... - Dec 10, 2007 CNNMoney.com...malignances and with Gemzar(R) and Taxotere(R) in solid tumors; and in four Phase II monotherapy clinical trials in hematological malignancies. Ariad's drug found effective against hematological cancers - Dec 10, 2007 Pharmaceutical Business ReviewWe are on track to enroll patients with CML and other hematological malignancies in our first clinical trial of oral AP24534 in early 2008." Preliminary Results from VioQuest Pharmaceuticals' Phase I Trial ... - Dec 10, 2007 Business Wire (press release),...a targeted inhibitor of Akt phosphorylation, which is currently being tested in Phase I clinical trials in both solid and hematological malignancies; Cord Blood Stem Cell Expansion: Increasing The Yield Of A Valuable ... - Dec 20, 2007 Medical News Today (press release),The trial will assess the efficacy and safety of expanded cord blood transplantation as a treatment for hematological malignancies, including leukemia and Cougar Biotechnology Initiates Phase I Trial for CB3304 (Noscapine) - Dec 23, 2007 dBusinessNews Los Angeles (press release),CB3304, an inhibitor of microtubule dynamics, which is currently in a Phase I trial in hematological malignancies and CB1089, an analog of vitamin D, MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve ... - Dec 11, 2007 CNNMoney.com...through these two mechanisms of epigenetic regulation has been demonstrated in vitro and in vivo in hematological malignancies and in solid tumors. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel ... - Dec 17, 2007 CNNMoney.com...pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. ARIAD Pharma Reveals Results Of Studies On Its Novel Kinase ... - Dec 8, 2007 Trading Markets (press release),The company stated that it is on track to enroll patients with CML and other hematological malignancies in its first clinical trial of oral AP24534 in early Three Astex Drug Candidates to be Presented at the 2007 American ... - Nov 28, 2007 PR Newswire (press release),...a Multitargeted Kinase Inhibitor, in Patients with Refractory Hematological Malignancies Session Name: Acute Myeloid Leukemias: Therapy, OXiGENE’s ZYBRESTAT TM Reported to Have Anti-Leukemic Effects in ... - Nov 28, 2007 Business Wire (press release),...efforts are focused, into hematological malignancies,� commented Dai Chaplin, Head of Research and Development and Chief Scientific Officer for OXiGENE. Geron Initiates Clinical Trial of Telomerase Inhibitor Drug in ... - Nov 28, 2007 Business Wire (press release),Multiple myeloma is the second most common hematological malignancy of adults, accounting for 10% of the diagnoses of hematological malignancies in the Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line ... - Dec 10, 2007 CNNMoney.comPixantrone is an investigational agent under development for the potential treatment of various hematological malignancies. It was developed to improve the Dacogen(R) (Decitabine) for Injection Data Presented at the ... - Dec 10, 2007 WELT ONLINE,We continue to evaluate Dacogen in a broad development program, which includes clinical studies in patients with MDS, AML, other hematological malignancies Ligand Presents Positive LGD-4665 Phase I Clinical Trial Results ... - Dec 8, 2007 WELT ONLINE,In addition, 50% of patients with certain hematological malignancies such as MDS suffer from disease-induced thrombocytopenia. LGD-4665 holds potential for Cyclacel Pharmaceuticals Provides Year End 2007 Pipeline Update ... - Dec 4, 2007 PR-USA.net (press release),Cyclacel will announce at the same time plans for Phase II development of sapacitabine in hematological malignancies. Fifteen patients have been enrolled in Gemin X Pharmaceuticals to Present Data on Obatoclax at American ... - Dec 3, 2007 PR-Inside.com (Pressemitteilung),Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by Continuous Infusion for up to Four Days to Patients with Hematological Malignancies. VioQuest Pharmaceuticals Announces Presentation on VQD-002 at the ... - Nov 27, 2007 Business Wire (press release),TCN-P) for advanced hematological malignancies will be presented at the 2007 American Society of Hematology (ASH) 49th Annual Meeting in Atlanta, GA, No Survival Advantage for High-dose Chemotherapy with Autologous ... - Dec 18, 2007 Cancer Consultants (press release),These data would suggest that the delivery of one or two high-dose treatments has less of an impact on breast cancer than on hematological malignancies such Gloucester Pharmaceuticals Announces Presentation of Romidepsin ... - Nov 29, 2007 ReutersRomidepsin is inclinical trials for a variety of other hematological malignancies andsolid tumors, including hormone refractory prostate cancer, MethylGene to Present Clinical Data for MGCD0103 at the 49th ... - Nov 29, 2007 Reuters...solid tumors and hematological malignancies, including Phase II monotherapy and Phase I/II combination trials with Vidaza(R), Gemzar(R) and Taxotere(R). Xanthus' Symadex Demonstrates Ability - Dec 11, 2007 Ad-Hoc-News (Pressemitteilung),Symadex is currently in a Phase 2 study for women with metastatic breast cancer, and has the potential to be active in hematological malignancies. Gloucester Pharmaceuticals Announces Positive Interim Results of ... - Dec 10, 2007 Business Wire (press release),Romidepsin is also in clinical trials for a variety of other hematological malignancies and solid tumors, including hormone refractory prostate cancer, Pluristem to Present at the Annual Meeting of the American Society ... - Dec 6, 2007 PharmaLive.com (press release),...to promote the engraftment of CD34+ human umbilical cord blood (hUCB) cells in patients afflicted with leukemia and other hematological malignancies. MethylGene to Present at the RBC Capital Markets 2007 Healthcare ... - Dec 5, 2007 Earthtimes,...for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I/II combination trials with Vidaza®, Gemzar® and Taxotere®. Gloucester Pharmaceuticals Announces Presentation Of Romidepsin ... - Dec 3, 2007 Medical News Today (press release),Romidepsin is in clinical trials for a variety of other hematological malignancies and solid tumors, including hormone refractory prostate cancer, BUYINS.NET: CGRB, TNXI, VYGO Have Also Been Added To Naked Short ... - Nov 29, 2007 Trading Markets (press release),...an inhibitor of microtubules and tubulin for the treatment of hematological malignancies; and CB-1089, an analog of vitamin D for various tumors, Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental ... - Nov 26, 2007 Trading Markets (press release),Pixantrone (BBR 2778) is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors and Search the web for more resources on Hematological malignancies |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2006 MONGABAY.COM |